We spoke with Dr Ramzi Ajjan (University of Leeds and Leeds Teaching Hospitals Trust) at Virtual EASD 2020 following the presentation of the results from the LIBERATES trial (improving gLucose control in patIents with diaBEtes following myocaRdial infArction: The role of a novEl glycaemic monitoring).
Disclosures: Ramzi Ajjan has received institutional research grants from Abbott, Bayer, Eli Lilly, Novo Nordisk, Roche, and Takeda and has received honoraria/education support and served as a consultant for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, and Takeda.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
